Skip to main content
Top
Published in: Annals of Hematology 10/2013

01-10-2013 | Letter to the Editor

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation

Authors: Massimo Breccia, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

Published in: Annals of Hematology | Issue 10/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, International Vidaza High-Risk MDS Survival Study Group et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedCrossRef Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, International Vidaza High-Risk MDS Survival Study Group et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedCrossRef
2.
go back to reference Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndrome. J Clin Oncol 29:516–523PubMedCrossRef Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndrome. J Clin Oncol 29:516–523PubMedCrossRef
3.
go back to reference Keating GM (2012) Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukemia. Drugs 72:1111–1136PubMedCrossRef Keating GM (2012) Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukemia. Drugs 72:1111–1136PubMedCrossRef
4.
go back to reference Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218–227PubMedCrossRef Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218–227PubMedCrossRef
5.
go back to reference Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G (2012) 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 53(8):1558–1560PubMedCrossRef Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G (2012) 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 53(8):1558–1560PubMedCrossRef
6.
go back to reference Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacitidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45:872–876PubMedCrossRef Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacitidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45:872–876PubMedCrossRef
7.
go back to reference Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R, Finke J (2010) Efficacy of a 3-day, low-dose treatment with 5-azacitidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627–632PubMedCrossRef Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R, Finke J (2010) Efficacy of a 3-day, low-dose treatment with 5-azacitidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627–632PubMedCrossRef
8.
go back to reference Ustun C, Kalla A, Farrow S, DeRemer DL, Jilella A (2008) Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol 83:825–827PubMedCrossRef Ustun C, Kalla A, Farrow S, DeRemer DL, Jilella A (2008) Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol 83:825–827PubMedCrossRef
Metadata
Title
Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation
Authors
Massimo Breccia
Adriano Salaroli
Alessandra Serrao
Giuliana Alimena
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1732-2

Other articles of this Issue 10/2013

Annals of Hematology 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.